To further enhance the potential utility of G-CSF to reduce delayed tPA treatment-induced outcomes and mortality, other preclinical assessments should be performed [13] in addition to the currently described procedure of testing the efficacy of G-CSF in different stroke models. This evidence concerns the gene PLAT and stroke disorder.